scholarly journals Classification and Progression Based on CFS-GA and C5.0 Boost Decision Tree of TCM Zheng in Chronic Hepatitis B

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Xiao Yu Chen ◽  
Li Zhuang Ma ◽  
Na Chu ◽  
Min Zhou ◽  
Yiyang Hu
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Decision Tree ◽  
Decision Trees ◽  
Chronic Hepatitis B ◽  
Public Health Problem ◽  
Attribute Selection ◽  
Stepwise Discriminant Analysis ◽  
Boost Decision Tree ◽  
C5.0 Decision Tree

Chronic hepatitis B (CHB) is a serious public health problem, and Traditional Chinese Medicine (TCM) plays an important role in the control and treatment for CHB. In the treatment of TCM, zheng discrimination is the most important step. In this paper, an approach based on CFS-GA (Correlation based Feature Selection and Genetic Algorithm) and C5.0 boost decision tree is used for zheng classification and progression in the TCM treatment of CHB. The CFS-GA performs better than the typical method of CFS. By CFS-GA, the acquired attribute subset is classified by C5.0 boost decision tree for TCM zheng classification of CHB, and C5.0 decision tree outperforms two typical decision trees of NBTree and REPTree on CFS-GA, CFS, and nonselection in comparison. Based on the critical indicators from C5.0 decision tree, important lab indicators in zheng progression are obtained by the method of stepwise discriminant analysis for expressing TCM zhengs in CHB, and alterations of the important indicators are also analyzed in zheng progression. In conclusion, all the three decision trees perform better on CFS-GA than on CFS and nonselection, and C5.0 decision tree outperforms the two typical decision trees both on attribute selection and nonselection.

scholarly journals Management of chronic hepatitis B before and after liver transplantation

2017 ◽  
Vol 9 (1) ◽  
pp. 79-84 ◽  
Author(s):  
B Wang ◽  
K Agarwal ◽  
D Joshi
Keyword(s):  
Liver Transplantation ◽  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Public Health Problem ◽  
Global Public Health ◽  
Chronic Hepatitis B Infection ◽  
Before And After ◽  
Related Liver Disease

Chronic hepatitis B infection is a global public health problem associated with significant morbidity and mortality. Persistent infection may evolve to liver cirrhosis and hepatocellular carcinoma, and hepatitis B-related liver disease is a common indication for liver transplantation. Patients with advanced liver disease should be treated with antiviral therapy which may result in clinical improvement. The management of patients after liver transplant then focuses on preventing hepatitis B recurrence in the graft. With the introduction of prophylactic treatment, patient and graft survival has improved significantly. In this review, we will discuss the management of patients with hepatitis B-related cirrhosis, both compensated and decompensated. We also review the management of hepatitis B after liver transplantation.

scholarly journals Comparison of the Characteristics of Hepatitis B Virus Whole Genomes Derived From Patients With Hepatocellular Carcinoma and Chronic Hepatitis B Infection

2020 ◽  
Author(s):  
Shuang Zhang ◽  
Feng Wang ◽  
He Liu ◽  
Qiudong Su ◽  
Feng Qiu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Public Health Problem ◽  
Full Length ◽  
Serum Samples ◽  
Hbv Genotypes ◽  
B Virus

Abstract Background: Hepatocellular carcinoma (HCC) caused by hepatitis B virus (HBV) infection is a serious public health problem in China. The aims of the present study was to report HCC prevalence in China and characterize the whole gene sequences of HBV derived from patients diagnosed with HCC as well as those with chronic hepatitis B (CHB) infections.Methods: Patients in the HCC group and the CHB group were recruited from national HBV surveillance sites, which were matched by age, gender, and region. All serum samples were tested for serological markers. Polymerase chain reaction (PCR) was used to amplify the HBV complete genome sequences. Then the analysis of the full-length HBV genomes was performed with bioinformatics and statistical software.Results: Serum samples were collected from 51 patients with HBV-related HCC and 76 patients with CHB. All patients were from six provinces (Guangxi, Hebei, Henan, Hunan, Qinghai, and Shanghai) in China. Sequencing and analysis of the full-length HBV genomes revealed the presence of four genotypes (B, C, CD, and I). The distribution of HBV genotypes and the positivity rate of the hepatitis B e antigen differed between the two groups. A total of 148 substitution sites deemed statistically significant were identified between the HCC and CHB groups. In addition, three mutational sites associated with HCC, (F22I/L/P in the pre-S2 region, P33S/T and S144A/T/V in the X region) were identified. Deletions to the pre-S and X regions were found in both HCC and CHB patients. However, deletions to the X region were more common in the HCC group than the CHB group.Conclusions: In this study the hotspot mutations associated with high risk of HCC mostly occurred in the sequences and some substitutions (C1470A/T, T1803A/G, and C1804T) that have not been previously reported. It was implicated that aa33 and aa144 substitution in X region may be new predictive markers for HCC. The results of our study would provide important basic information for HCC prevention.

scholarly journals Successful lamivudine therapy for chronic hepatitis B in the family

2006 ◽  
Vol 63 (5) ◽  
pp. 504-507
Author(s):  
Darko Nozic
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Public Health Problem ◽  
Global Public Health ◽  
Virus Genotype ◽  
Lamivudine Therapy ◽  
B Virus ◽  
Current Therapies ◽  
Previously Treated

Background. Hepatitis B virus infection is a global public health problem since it is a leading cause of liver cirrhosis and hepatocellular carcinoma. An optimal treatment is needed to reduce mortality. Current therapies for chronic hepatitis B include standard and pegilated interferon-alfa and nucleoside and nucleotide analogies, primarily lamivudine and adefovir. Each of the therapies, however has various limitations. Case report. In this paper we presented a father and his daughter with chronic hepatitis B, successfully treated with lamivudine. Conclusion. In the linked cases of chronic hepatitis B, the choice of antiviral medicine in some patients could also be made on the basis of its efficacy in the persons previously treated with it, even without determining virus genotype.

scholarly journals VIRAL COINFECTIONS IN PATIENTS WITH CHRONIC HEPATITIS B: THEIR PREVALENCE AND CLINICAL SIGNIFICANCE

2020 ◽  
Vol 4 (2) ◽  
pp. 171-176
Author(s):  
D. V. Tserashkou ◽  
◽  
V. M. Mitsura ◽  
E. V. Voropaev ◽  
O. V. Osipkina ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Public Health Problem ◽  
Global Public Health ◽  
Biochemical Tests ◽  
Chronic Hepatitis B Virus ◽  
B Virus

Background. Hepatitis B virus (HBV) infection remains a global public health problem. Objective – to analyze the prevalence of viral coinfections with human immunodefciency virus (HIV), hepatitis C virus (HCV), hepatitis delta virus (HDV), TT-viruses and SENV in patients with chronic hepatitis B (CHB) and to assess their influence on liver disease severity. Material and methods. The observational cross-sectional study included 287 patients with chronic hepatitis B virus (HBV) – those with monoinfection and coinfected with HIV, HCV, HDV. Routine hematological and biochemical tests were performed, serum HBV DNA level as well as liver fbrosis stage were measured. Blood samples from 62 patients for Torque teno virus (TTV), Torque teno mini virus, Torque teno midi virus, SENV (D and H genotypes) DNAs were examined by polymerase chain reaction. Results. Among patients with CHB the prevalence of coinfection HBV + HIV is 6.6%, HBV + HCV – 6.3%, HBV + HDV – 3.8% and HBV + HDV + HCV – 1.7%. CHB patients coinfected with HIV, HCV, HDV had more pronounced biochemical differences and higher proportion of liver cirrhosis vs. HBV-monoinfected ones. The detection rate of TT viruses and their various combinations in patients with CHB is 91.9%, SENV – 66.1%. Conclusion. Coinfection with HIV, HCV, HDV in CHB patients is associated with more severe forms of chronic liver disease as compared to HBV-monoinfection. TT viruses and SENV are widespread and don’t affect the severity of liver disease in patients with CHB.

Sign in / Sign up

Export Citation Format

Share Document